Taysha Gene Therapies (TSHA) Retained Earnings (2019 - 2026)

Taysha Gene Therapies (TSHA) has 8 years of Retained Earnings data on file, last reported at -$753.7 million in Q1 2026.

• For the quarter ending Q1 2026, Retained Earnings fell 20.82% year-over-year to -$753.7 million; the trailing twelve-month figure through Mar 2026 stood at -$753.7 million (down 20.82% YoY), and the FY2025 full-year result was -$711.3 million, down 204.93% from the prior year.
• Retained Earnings eased to -$753.7 million in Q1 2026, from -$711.3 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $677.9 million in Q4 2024 to a low of -$753.7 million in Q1 2026.
• A 5-year average of -$113.0 million and a median of -$285.8 million in 2022 frame the typical range for Retained Earnings.
• Across the five-year window, Retained Earnings jumped 247.9% in 2023 and tumbled 29257.77% in 2025, its largest moves.
• Tracing TSHA's Retained Earnings over 5 years: stood at $402.4 million in 2022, then surged by 46.11% to $587.9 million in 2023, then gained by 15.29% to $677.9 million in 2024, then tumbled by 204.93% to -$711.3 million in 2025, then decreased by 5.96% to -$753.7 million in 2026.
• Business Quant data shows TSHA's Retained Earnings at -$753.7 million in Q1 2026, -$711.3 million in Q4 2025, and -$683.4 million in Q3 2025.